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Summary
Objectives: We aimed to evaluate the clinical and microbiological characteristics of the patients
who developed an infection in our surgical intensive care unit (SICU).
Methods: This was a prospective study of all patients who sustained an ICU-acquired infection
from 2002 to 2004.
Results: Among 683 consecutive SICU patients, 123 (18.0%) developed 241 infections (48.3
infections per 1000 patient-days). The mean age of patients was 66.7  3.8 years, the mean
APACHE II score (acute physiology and chronic health evaluation) on SICU admission was
18.2  2.4, and the mean SOFA score (sepsis-related organ failure assessment) at the onset of
infection was 8.8  2. Of the study patients, 51.2% were women. Infections were: bloodstream
(36.1%), ventilator-associated pneumonia (VAP; 25.3%, 20.3/1000 ventilator-days), surgical site
(18.7%), central venous catheter (10.4%, 7.1/1000 central venous catheter-days), and urinary
tract infection (9.5%, 4.6/1000 urinary catheter-days). The most frequent microorganisms found
were: Acinetobacter baumannii (20.3%), Pseudomonas aeruginosa (15.7%), Candida albicans
(13.2%), Enterococcus faecalis (10.4%), Klebsiella pneumoniae (9.2%), Enterococcus faecium
(7.9%), and Staphylococcus aureus (6.7%). High resistance to the majority of antibiotics was
identified. The complication andmortality rates were 58.5% and 39.0%, respectively. Multivariate
analysis identified APACHE II score on admission (odds ratio (OR) 4.63, 95% confidence interval (CI)
2.69—5.26, p = 0.01), peritonitis (OR 1.85, 95% CI 1.03—3.25, p = 0.03), acute pancreatitis (OR
2.27, 95% CI 1.05—3.75, p = 0.02), previous aminoglycoside use (OR 2.84, 95% CI 1.06—5.14,
p = 0.03), and mechanical ventilation (OR 3.26, 95% CI: 2.43—6.15, p = 0.01) as risk factors for
infection development. Age (OR 1.16, 95% CI 1.01—1.33, p = 0.03), APACHE II score on admission* Corresponding author. Tel.: +30 697 6788806; fax: +30 210 7790518.
E-mail address: markogiannakis@yahoo.com (H. Markogiannakis).
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(OR 2.53, 95% CI 1.77—3.41, p = 0.02), SOFA score at the onset of infection (OR 2.88, 95% CI 1.85—
4.02, p = 0.02), and VAP (OR 1.32, 95% CI 1.04—1.85, p = 0.03) were associated with mortality.
Conclusions: Infections are an important problem in SICUs due to high incidence, multi-drug
resistance, complications, and mortality rate. In our study, APACHE II score on admission,
peritonitis, acute pancreatitis, previous aminoglycoside use, and mechanical ventilation were
identified as risk factors for infection development, whereas age, APACHE II score on admission,
SOFA score at the onset of infection, and VAP were associated with mortality.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Nosocomial infections are a common, severe problem world-
wide, associated with significant morbidity and mortality as
well as rapidly increasing multi-drug resistance of the respon-
sible microorganisms to antibiotics.1—6 Intensive care unit
(ICU) patients are at greater risk of developing a hospital
infection and, moreover, resistance rates of pathogens iso-
lated in ICU infections toantimicrobial agents are substantially
higher than those in community and other hospital ward
infections.1,5—9 The high incidence of infection andmulti-drug
resistance in ICU patients is attributable to severe underlying
medical condition, frequent and, sometimes, unnecessary use
of broad-spectrum antibiotics, mechanical ventilation, utili-
zation of several devices placed with interventional techni-
ques, prolonged hospital stay, and greater risk of cross-
transmission of resistant microorganisms.1,5—7,9—12
Significant differences with regard to infection rates, the
rates of occurrence of organisms, infection sites incidence,
and antimicrobial resistance profiles have been identified
among different countries, among centers in the same
country, and even among the departments of a hospital.1—
4,7,9—12 Such discrepancies emphasize the importance of
local surveillance in the prevention, control, and treatment
of infections. The objective of the present prospective
observational study was the identification and analysis of
the demographic, clinical, and microbiological character-
istics of the patients who developed an ICU-acquired infec-
tion during their hospitalization in the surgical intensive
care unit (SICU) of our hospital. In particular, we evaluated
the incidence and associated morbidity and mortality of
infections along with the occurrence rates of the pathogens
and their susceptibility to antibiotics. Furthermore, we
investigated potential risk factors for infection as well as
for infection-related mortality.
Materials and methods
Study patients
This prospective study was conducted in the SICU of the 1st
Department of Propaedeutic Surgery, Hippokrateion Hospi-
tal, University of Athens. All adult patients (aged over 14
years) who developed an ICU-acquired infection, according
to the standard Centers for Disease Control and Prevention
(CDC) criteria13,14 (National Healthcare Safety Network
(NHSN) criteria) and International Sepsis Forum (ISF) cri-
teria,15 regardless of infection site, from January 1, 2002
to December 31, 2004 were included in our study. Coloniza-
tions, defined as any positive culture without clinical signs ofinfection, were excluded. Infections occurring prior to
patient SICU admission or in the first 48 hours of SICU hospi-
talization and after the first 48 hours following discharge
from the SICU to the ward were also excluded. Patients under
14 years are not hospitalized in our unit since there is no
pediatric or pediatric surgical department in our hospital.
Institutional review board approval was obtained before
study initiation.
Data collection and microbiological analysis
Complete data of all patients hospitalized in our SICU (includ-
ing information prior to SICU admission, during SICU hospi-
talization until discharge or death, and after discharge from
the SICU until discharge from the hospital) are collected on a
daily basis through our unit’s computerized registry, starting
immediately from patient SICU admission.
Patients with ICU-acquired infection were identified and
followed prospectively from the date of infection to hospital
discharge or death. Isolates were considered duplicates and
excluded from the database if they were collected over a 7-
day period from the same patient and were of the same
bacterial species and had identical antibiograms. Identical
isolates from different specimen sources collected within the
same 7-day period were also excluded.
Isolates were identified by conventional methods. Anti-
microbial resistance was determined according to the
guidelines of the National Committee for Clinical Labora-
tory Standards (NCCLS).16 Intermediate susceptibility was
regarded as resistance.
Cultures were performed based on the clinical picture of
the patient. All patients with clinical signs of infection
received empirical antimicrobial therapy. After culture
results were known, administered antibiotics were main-
tained or adapted on the basis of standard sensitivity testing.
Regarding diagnosis of ventilator-associated pneumonia
(VAP), diagnosis required a radiographic image of a new,
progressive and persistent pulmonary infiltrate not otherwise
explained on chest X-ray and at least two of the following
criteria: temperature >38 8C or <35.5 8C, white blood cell
count>12  109/l or<4  109/l, PaO2/FiO2<240, and puru-
lent bronchial secretions. Moreover, a positive quantitative
culture of a bronchoalveolar lavage (BAL) specimen was
required. Fiberoptic bronchoscopic examination using BAL
was performed on all these patients. The diagnosis of VAP was
made only if quantitative cultures of BAL specimens yielded
>104 cfu/ml. Finally, a pneumonia was considered VAP when
its onset occurred at >48 hours following initiation of
mechanical ventilation and was judged not to have been
incubated before starting mechanical ventilation.
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history, underlying surgical pathology (hospital admission
diagnosis), APACHE II score (acute physiology and chronic
health evaluation)17 on the day of SICU admission, SOFA score
(sepsis-related organ failure assessment)18 on the day of
infection diagnosis, type of management (conservative or
operative), days in hospital before SICU admission, antibio-
tics prior to the day of the onset of infection (exposure, type
and duration), presence and duration of invasive procedures
(ventilator, arterial, central and peripheral venous lines,
urinary catheters), days of SICU hospitalization and post-
operative days until infection, infection site, microorganismsTable 1 Univariate comparison of demographic and clinical data
Variable Infection (N =
Age (years) a 66.7  3.8 (2
Female genderb 63 (51.2%)
APACHE II score on admissiona 18.2  2.4 (8
SOFA score on the day of infectiona 8.8  2 (0—
Medical historyb
Cardiovascular disease 55 (44.7%)
Respiratory disease 26 (21.1%)
Diabetes mellitus 19 (15.4%)
Cancer 11 (8.9%)
Renal disease 5 (4.1%)
Corticosteroid use 3 (2.4%)
Surgical pathologyb
Gastrointestinal cancer 46 (37.4%)
Peritonitis 20 (16.3%)
Intestinal obstruction 15 (12.2%)
Acute pancreatitis 12 (9.8%)
Gastrointestinal hemorrhage 9 (7.3%)
Superior mesentery artery infarction 6 (4.9%)
Acute cholangitis 6 (4.9%)
Acute cholecystitis 5 (4.1%)
Abdominal trauma 4 (3.3%)
Operationb 109 (88.6%)
Reoperationb 20 (16.3%)
Days in hospital before SICUc 2 (1—3)
Days in SICU before infectionc 7 (3—13)
Postoperative days before infectionc 6 (4—11)
Prior aminoglycoside administrationb 42 (34.1%)
Prior carbapenem administrationb 27 (22.0%)
Days of previous aminoglycoside usec 4 (3—6)
Days of previous carbapenem usec 4 (3—7)
Mechanical ventilationb 76 (61.8%)
Mechanical ventilation daysc 11 (4—22)
Central venous catheter daysc 12 (6—20)
Urinary catheter daysc 13 (10—24)
Complicationsb 72 (58.5%)
SICU mortalityb 48 (39.0%)
Total ICU stay (days) c 14 (7—28)
Total hospital stay (days) c 25 (18—36)
NS, not statistically significant; APACHE, acute physiology and chronic
SICU, surgical intensive care unit.
a Values are presented as mean  SE (standard error of the mean) an
b Values are presented as number of patients and percentage (in par
c Values are presented as median and interquartile range (in parenthand their susceptibility to antibiotics, complications (such as
organ/system failure, peritonitis, and hemorrhage), length
of SICU and hospital stay, and final outcome.
Prior exposure to antimicrobial agents was defined as at
least 48 hours of therapy during the 14 days before the day of
the onset of infection, i.e., before the day that the patients
presented clinical signs of infection. Antibiotics administered
on the day of the onset of infection until the culture results
became available, given as empiric therapy, were not con-
sidered as antibiotics prior to infection and were, thus, not
included in the analysis. Organ/system failure was defined
according to the American College of Chest Physicians (ACCP)of the patients with and without infection
123) No infection (N = 560) p-Value
5—86) 64.9  2.6 (23—80) NS
297 (53.0%) NS
—30) 8.3  3.1 (5—14) 0.001
16)
NS
252 (45%)
112 (20%)
78 (13.9%)
45 (8.0%)
23 (4.1%)
12 (2.1%)
251 (44.8%) NS
60 (10.7%) 0.04
85 (15.2%) NS
26 (4.6%) 0.02
50 (8.9%) NS
10 (1.8%) 0.03
30 (5.4%) NS
33 (5.9%) NS
15 (2.7%) NS
476 (85%) NS
60 (10.7%) 0.04
2 (1—3) NS
39 (7.0%) 0.01
11 (2.0%) 0.02
0 (0—2) 0.01
0 (0—2) 0.01
80 (14.3%) 0.001
1 (0—3) 0.001
2 (1—3) 0.01
3 (1—4) 0.01
72 (12.9%) 0.001
21 (3.8%) 0.001
4 (2—7) 0.02
10 (8—14) 0.02
health evaluation; SOFA, sepsis-related organ failure assessment;
d range (in parenthesis).
enthesis).
esis).
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as the SCCM/European Society of Intensive Care Medicine
(ESICM)/ACCP/American Thoracic Society (ATS)/Surgical
Infection Society (SIS) criteria.20
Statistical analysis
Data regarding the demographic and clinical features of the
patients, the incidence and associated complications and
mortality of infections, infection sites, microorganism occur-
rence rates in the total of infections and per infection type,
and antimicrobial susceptibility were analyzed. Moreover,
potential risk factors for the development of infection and
for infection-related mortality were investigated. Particu-
larly, patients with ICU-acquired infection were compared
with patients who did not sustain an infection, using uni-
variate and multivariate analysis, in order to identify pre-
disposing factors for infection in the patients hospitalized in
our SICU during the study period. Additionally, comparison
between patients with infection who survived and those who
died was performed, using both univariate and multivariate
analysis, in order to identify risk factors for mortality in the
patients who sustained infection.
Univariate analysis was conducted using the Student’s t-
test and Mann—Whitney test for numeric variables and Chi-
square and Fisher’s exact test for categorical variables.
Multivariate analysis was performed with a logistic regression
model in order to identify independent risk factors for infec-
tion development and mortality, respectively. Only variables
occurring prior to infection were analyzed as possible pre-
disposing factors for infection development whereas all vari-
ables were used for mortality. Data are presented as
mean  SE (standard error of the mean) and number of
patients or infections and percentage unless otherwise spe-
cified. Length of utilization of invasive devices, antibiotic
use, and SICU and hospital stay are presented as median with
interquartile range. Statistical significance was set to
p < 0.05. Results in multivariate analyses are also presented
with odds ratios (OR) and 95% confidence intervals (95% CI).
Results
During the 3-year study period, 683 consecutive patients were
hospitalized in our SICU; 123 patients (18.0%) developed an
infection and formed the study group. The mean age of theTable 2 Incidence of infections
Infections Number of
infections (N = 241)a
Per 1000
patient-days
Bloodstream 87 (36.1%) 17.4
VAP 61 (25.3%) 12.2
Surgical site 45 (18.7%) 9
CV catheter 25 (10.4%) 5.1
Urinary tract 23 (9.5%) 4.6
SICU, surgical intensive care unit; VAP, ventilator-associated pneumon
a Values in this column are presented as number of infections and pe
b Ventilator-associated pneumonias are expressed per 1000 ventilato
catheter-days, and urinary tract infections per 1000 urinary catheter-
c Values are presented as number of study patients who developed e
d Values are presented as number of patients hospitalized in the SICpatientswas 66.7  3.8 years, themeanAPACHE II scoreon the
dayof SICUadmissionwas18.2  2.4, and themeanSOFA score
on the day of infection diagnosis was 8.8  2. Fifty-three
patients (43.1%) developed one infection, 50 (40.6%) two,
and 20 (16.3%) more than two infections.
Demographic and clinical features of the patients with
infection and those who did not develop an infection are
presented in Table 1. Comparison of these two groups of
patients using univariate analysis revealed significant differ-
ences in APACHE II score on admission ( p = 0.001), peritonitis
( p = 0.04), acute pancreatitis ( p = 0.02), and superior
mesentery artery infarction ( p = 0.03) as the underlying
surgical pathology, reoperation ( p = 0.04), previous use of
an aminoglycoside or carbapenem ( p = 0.01 and p = 0.02,
respectively), duration of previous aminoglycoside or carba-
penem administration ( p = 0.01), mechanical ventilatory
support and days in ventilator ( p = 0.001), length of central
venous and urinary catheter utilization ( p = 0.01), complica-
tions ( p = 0.001), SICU mortality ( p = 0.001), and length of
total SICU and hospital stay ( p = 0.02) (Table 1). Further-
more, multivariate analysis identified APACHE II score on
admission (OR 4.63, 95% CI 2.69—5.26, p = 0.01), peritonitis
(OR 1.85, 95% CI 1.03—3.25, p = 0.03), acute pancreatitis (OR
2.27, 95% CI 1.05—3.75, p = 0.02), previous aminoglycoside
administration (OR 2.84, 95% CI 1.06—5.14, p = 0.03), and
mechanical ventilation (OR 3.26, 95% CI 2.43—6.15, p = 0.01)
as independent risk factors for infection development.
The study group sustained 241 infections (48.3 infections
per 1000 patient-days). Infections and incidence of each
infection among study patients and the total of SICU patients
as well as per 1000 patient-days and 1000 device-days are
described in Table 2. Bloodstream infections and VAP were
the most common infections.
Acinetobacter baumannii (20.3%), Pseudomonas aerugi-
nosa (15.7%), Candida albicans (13.2%), Enterococcus faeca-
lis (10.4%), Klebsiella pneumoniae (9.2%), Enterococcus
faecium (7.9%), and Staphylococcus aureus (6.7%) were
the most frequent organisms identified. The rates of patho-
gen groups are presented in Table 3 and antimicrobial sus-
ceptibility of Gram-positive and Gram-negative organisms in
Table 4. High resistance to the majority of antibiotics was
found.
The overall complication rate for the study patients was
58.5% (n = 72). Particularly, the most common complication
after the diagnosis of infection was septic shock (n = 48,Per 1000
device-daysb
Infected
patients (N = 123) c
All SICU patients
(N = 683)d
73 (59.3%) 73 (10.6%)
20.3 45 (36.6%) 45 (6.6%)
31 (25.2%) 31 (4.5%)
7.1 20 (16.3%) 20 (2.9%)
4.6 22 (17.9%) 22 (3.2%)
ia; CV, central venous.
rcentage (in parenthesis).
r-days, central venous catheter infections per 1000 central venous
days.
ach infection and percentage (in parenthesis).
U who developed each infection and percentage (in parenthesis).
Table 3 Rates of microorganism groups in the total infections, per infection, and per 1000 patient- and device-days
Microorganism group Bloodstream VAP Surgical site CV catheter Urinary tract Total
Gram-positive 49 (56.3%)a 2 (3.3%) a 17 (37.8%)a 6 (24%)a 1 (4.4%)a 75 (31.1%)a
[65.3%]b [2.7%]b [22.7%]b [8%]b [1.3%]b [100%]b
9.8c 0.4c 3.4c 1.2c 0.2c 15c
0.7d 1.8e 0.2 f
Gram-negative 35 (40.2%)a 49 (80.3%)a 20 (44.4%)a 17 (68%)a 11 (47.8%)a 132 (54.8%)a
[26.5%]b [37.1%]b [15.2%]b [12.9%]b [8.3%]b [100%]b
7c 9.8c 4.2c 3.5c 2.2c 26.7c
16.3d 4.7e 2.2 f
Fungi 3 (3.5%)a 10 (16.4%)a 8 (17.8%)a 2 (8%)a 11 (47.8%)a 34 (14.1%)a
[8.8%]b [29.4%]b [23.5%]b [5.9%]b [32.4%]b [100%]b
0.6c 2c 1.4c 0.4c 2.2c 6.6c
3.3d 0.6e 2.2 f
Total 87 (100%)a 61 (100%)a 45 (100%)a 25 (100%)a 23 (100%)a 241 (100%)a
[36.1%]b [25.3%]b [18.7%]b [10.4%]b [9.5%]b [100%]b
17.4c 12.2c 9c 5.1c 4.6c 48.3c
20.3d 7.1e 4.6 f
VAP, ventilator-associated pneumonia; CV, central venous.
a Values are presented as number of infections and percentage (percentages in parenthesis refer to each column, i.e., per each infection).
b Values are presented as number of infections and percentage (percentages in brackets refer to each row, i.e., per each microorganism
group).
c Values are presented as number of infections/1000 patient-days.
d Values are presented as number of infections/1000 ventilator-days.
e Values are presented as number of infections/1000 central venous catheter-days.
f Values are presented as number of infections/1000 urinary catheter-days.
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renal failure (n = 35, 28.5%), while 20 patients (16.3%) devel-
oped heart failure, 20 (16.3%) thrombocytopenia, 13 (10.6%)
coagulopathy, and 13 (10.6%) hepatic failure. In addition,
postoperative complications were peritonitis (n = 7, 5.7%)
and hemorrhage (n = 2, 1.6%).
Moreover, SICU mortality of the study group was high
(39.0%, n = 48). Univariate comparison of the patients with
infection who survived and those with infection who died
revealed statistically significant differences in age
( p = 0.04), APACHE II score on the day of SICU admission
( p = 0.001) and SOFA score on the day of infection diagnosis
( p = 0.001), acute pancreatitis ( p = 0.03) and superior
mesentery artery infarction ( p = 0.02), VAP ( p = 0.001), E.
faecium infection ( p = 0.001), mechanical ventilation prior
to infection ( p = 0.01), complications ( p = 0.001), and length
of total SICU and hospital stay ( p = 0.02) (Table 5). Finally,
multivariate analysis identified age (OR 1.16, 95% CI 1.01—
1.33, p = 0.03), APACHE II score on admission (OR 2.53, 95% CI
1.77—3.41, p = 0.02), SOFA score on the day of infection (OR
2.88, 95% CI 1.85—4.02, p = 0.02), and VAP (OR 1.32, 95% CI
1.04—1.85, p = 0.03) as independent risk factors for mortality
of patients with infection.
Discussion
The search for themeans to understand, control, and prevent
the emergence and spread of infections and antimicrobial
resistance has become a public health priority.1,5,6,21 The
prevention, control, and treatment of ICU infections demand
thorough knowledge of the infection incidence and infection
sites rates, the occurrence rates of organisms and theirantimicrobial resistance profiles, and potential risk factors
for infection and infection-associated mortality. The objec-
tive of this study was to identify and analyze the clinical and
microbiological features of the patients who developed an
ICU-acquired infection in our SICU, and to evaluate risk
factors associated with infection development and infec-
tion-related mortality.
In agreement with the literature, the incidence of total
infections in our patients was quite high (18.0% of the total of
SICU hospitalized patients or 48.3 infections per 1000
patient-days).1,4,9,12,22 Recorded infections were blood-
stream, VAP, surgical site, central venous catheter, and
urinary tract infections, with bloodstream and VAPrepresent-
ing the majority of them. The higher incidence of blood-
stream infections than VAP and, also, than that usually
reported in other series, may be explained by the fact that
only cases with underlying surgical pathology, mostly of
general surgery, are admitted to our unit and, moreover,
approximately 90% of the study patients underwent abdom-
inal surgery, particularly gastrointestinal surgical proce-
dures. Surgery and especially gastrointestinal operations
have been shown to increase intestinal permeability resulting
in bacterial translocation. Therefore, some of these blood-
stream infections may have an intestinal origin due to bac-
terial translocation. This may also be implied by our finding
that A. baumannii, E. faecium, and E. faecalis caused 46% of
such infections.
Regarding the microbiological profile of the total of infec-
tions, A. baumannii, P. aeruginosa, C. albicans, E. faecalis, K.
pneumoniae, E. faecium, and S. aureusweremore frequently
isolated; similar results have also been found in other stu-
dies.1,3,4,7,8,11,12,22,23 A. baumannii was the most common,
Table 4 Susceptibility of the most frequent Gram-negative and Gram-positive microorganisms to antibiotics
Antibiotic Microorganism
Acinetobacter
baumannii
Pseudomonas
aeruginosa
Klebsiella
pneumoniae
Enterococcus
faecalis
Enterococcus
faecium
Staphylococcus
aureus
Methicillin 12% 10.5% 12.5%
Amoxicillin—clavulanate 4% 7.9% 9.1% 8% 0% 6.2%
Ampicillin—sulbactam 26.5% 7.9% 13.6% 16% 5.2% 6.2%
Piperacillin—tazobactam 4% 57.9% 13.6% 20% 15.8% 12.5%
Ticarcillin—clavulanate 2% 39.5% 9.1% 16% 5.2% 6.2%
Ceftazidime 8.1% 60.5% 18.2%
Cefepime 6.1% 47.3% 27.2%
Gentamicin 10.2% 60.5% 40.9% 32% 26.3% 25%
Tobramycin 30.6% 55.2% 13.6% 16% 21% 25%
Netilmycin 24.5% 63.1% 31.8% 16% 26.3% 18.7%
Amikacin 24.5% 55.2% 31.8% 16% 21% 18.7%
Imipenem 24.5% 65.8% 72.7%
Meropenem 14.3% 50% 63.6%
Aztreonam 2% 55.2% 36.3%
Ciprofloxacin 4% 55.2% 27.2% 16% 15.8% 25%
Levofloxacin 4% 55.2% 27.2% 16% 15.8% 25%
Clindamycin 0% 15.8% 12.5%
Tetracycline 12% 15.8% 18.7%
Erythromycin 4% 0% 12.5%
Rifampin 24% 26.3% 37.5%
Vancomycin 76% 63.1% 93.7%
Teicoplanin 80% 63.1% 93.7%
Linezolid 100% 100% 100%
Colistin 100% 100% 100%
150 H. Markogiannakis et al.while P. aeruginosa and C. albicanswere the second and third
most frequently identified pathogen in our study population,
respectively.
Themajor pathogens causing bloodstream infections were
A. baumannii, E. faecium, E. faecalis, S. aureus, and Sta-
phylococcus epidermidis, whereas for VAP they were A.
baumannii, P. aeruginosa, C. albicans, and K. pneumoniae.
These findings are in accordance with the literature.1,10—
12,22,23 The predominant microorganisms in surgical site
infections were E. faecalis, C. albicans, A. baumannii, and
E. faecium and in central venous catheter infections P.
aeruginosa and A. baumannii.11,12 Finally, C. albicans and
Escherichia coliwere over-represented in urinary tract infec-
tions as also reported in other studies.11,12,23,24
Regarding isolation sites of the microorganisms, similarly
to several studies in the literature, the most frequent infec-
tions by A. baumannii and P. aeruginosa in our patients were
VAP and bloodstream infections,12,22,23,25,26 while C. albicans
was more often identified in urinary tract infections and
VAP.24 Bloodstream and surgical site infections were the
predominant infections by E. faecalis and E. faecium, K.
pneumoniae was more frequently isolated from bloodstream
and VAP, whereas the majority of S. aureus infections were
bacteremias. These results are also in accordance with those
observed in other series.10—12,23
However, unlike several studies in the literature, VAP due
to C. albicans in our study was quite high. The incidence of
Candida pneumonia varies among different studies with data
from several studies showing an incidence varying from 0% to
4.5%.27,28 In a study by Palabiyikog˘lu et al., Candida coloni-zation incidence in endotracheal aspirates was 12% and
Candida pneumonia incidence 2%.27 However, el-Ebiary
et al., in a study of 25 non-neutropenic, mechanically venti-
lated (>72 hours) patients, found an incidence of Candida
isolation from lung biopsies of 40% with definite Candida
pneumonia in 8%.28 The criteria for diagnosis of pulmonary
candidiasis are controversial.27,28 Moreover, the value of
quantitative cultures of respiratory samples in the diagnosis
of Candida pneumonia has not been thoroughly evalu-
ated.27,28 Despite the debate about the diagnosis of pulmon-
ary candidiasis, the definite diagnosis of pulmonary
candidiasis still rests on histologic demonstration of Candida
in lung tissue with associated inflammation.27,28 In our study,
however, such histologic demonstration was not performed,
but positive quantitative culture results of BAL specimens
together with the described radiologic and clinical criteria
were required for VAP diagnosis. Furthermore, we believe
that the number of patients with VAP (n = 61) and, particu-
larly, the number of patients with VAP due to C. albicans
(n = 10) in the presented study are very small in order to draw
any conclusions or to evaluate this result. This specific finding
should, therefore, be interpreted with great caution.
Prolonged SICU and hospital stay, significant resistance of
the pathogens to the majority of antibiotics, as well as high
complication and SICU mortality rates of our patients were
found. More importantly, comparison of hospitalized patients
in our SICU developing infection with those without an
infection revealed that patients with infection had signifi-
cantly longer SICU and hospital stays along with higher
complication and mortality rates. These findings indicate
Table 5 Comparison between patients with infection who survived and those who died (univariate analysis)
Variable Non-survivors (N = 48) Survivors (N = 75) p-Value
Age (years) a 71.3  8.7 (25—80) 62.4  10.3 (30—86) 0.04
Female genderb 24 (50%) 39 (52%) NS
APACHE II score on admissiona 25.2  6.5 (10—30) 10.7  5.6 (8—14) 0.001
SOFA score on the day of infectiona 10.9  2 (4—16) 4  1 (0—6) 0.001
Medical historyb NS
Cardiovascular disease 23 (47.9%) 32 (42.7%)
Respiratory disease 10 (20.8%) 16 (21.3%)
Diabetes mellitus 8 (16.7%) 11 (14.7%)
Cancer 4 (8.3%) 7 (9.3%)
Renal disease 2 (4.2%) 3 (4%)
Corticosteroid use 1 (2.1%) 2 (2.7%)
Surgical pathologyb
Gastrointestinal cancer 16 (33.3%) 30 (40%) NS
Peritonitis 7 (14.6%) 13 (17.3%) NS
Intestinal obstruction 5 (10.4%) 10 (13.3%) NS
Acute pancreatitis 7 (14.6%) 5 (6.7%) 0.03
Gastrointestinal hemorrhage 3 (6.3%) 6 (8%) NS
Superior mesentery artery infarction 4 (8.3%) 2 (2.7%) 0.02
Acute cholangitis 2 (4.2%) 4 (5.3%) NS
Acute cholecystitis 2 (4.2%) 3 (4%) NS
Abdominal trauma 2 (4.2%) 2 (2.7%) NS
Infectionb
Bloodstream 34 (70.8%) 39 (52%) NS
Ventilator-associated pneumonia 33 (68.8%) 12 (16%) 0.001
Surgical site 17 (35.4%) 14 (18.7%) NS
Central venous catheter 8 (16.7%) 12 (16%) NS
Urinary tract 8 (16.7%) 14 (18.7%) NS
Microorganismb
Acinetobacter baumannii 10 (20.8%) 12 (16%) NS
Pseudomonas aeruginosa 7 (14.6%) 11 (14.7%) NS
Candida albicans 7 (14.6%) 10 (13.3%) NS
Enterococcus faecalis 7 (14.6%) 10 (13.3%) NS
Klebsiella pneumoniae 4 (8.3%) 8 (10.7%) NS
Enterococcus faecium 10 (20.8%) 2 (2.7%) 0.001
Staphylococcus aureus 3 (6.3%) 5 (6.7%) NS
Staphylococcus epidermidis 3 (6.3%) 4 (5.3%) NS
Operationb 42 (87.5%) 67 (89.3%) NS
Reoperationb 7 (14.6%) 13 (17.3%) NS
Days in hospital before SICUc 2 (1—3) 2 (1—3) NS
Days in SICU before infectionc 7 (5—14) 7 (3—12) NS
Aminoglycoside before infectionb 16 (33.3%) 26 (34.7%) NS
Carbapenem before infectionb 10 (20.8%) 17 (22.7%) NS
Aminoglycoside days before infectionc 4 (3—6) 4 (3—7) NS
Carbapenem days before infectionc 4 (3—7) 4 (3—6) NS
Mechanical ventilation before infectionb 40 (83.3%) 36 (48%) 0.01
Mechanical ventilation days before infectionc 11 (4—20) 10 (3—16) NS
Central venous catheter days before infectionc 10 (6—15) 11 (5—17) NS
Urinary catheter days before infectionc 11 (8—14) 12 (6—18) NS
Complicationsb 41 (85.4%) 31 (41.3%) 0.001
Total ICU stay (days) c 19 (9—28) 11 (5—19) 0.02
Total hospital stay (days) c 29 (14—36) 17 (9—24) 0.02
NS, not statistically significant; APACHE, acute physiology and chronic health evaluation; SOFA, sepsis-related organ failure assessment;
SICU, surgical intensive care unit.
a Values are presented as mean  SE (standard error of the mean) and range (in parenthesis).
b Values are presented as number of patients and percentage (in parenthesis).
c Values are presented as median and interquartile range (in parenthesis).
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infections in ICU patients. Several studies also suggest that
ICU infections are associated with prolongation of hospitali-
zation time and high multi-drug resistance, morbidity and
mortality.1,2,4—6,9,22,25
Univariate analysis for infection development risk factors
in our patients showed a significant association with APACHE II
score on admission, underlying surgical pathology (namely,
peritonitis, acute pancreatitis, and superior mesentery
artery infarction), reoperation, previous exposure to and
duration of aminoglycoside or carbapenem administration,
and utilization of invasive devices such as ventilator and
central venous and urinary catheters. Moreover, multivariate
analysis identified APACHE II score on the day of SICU admis-
sion, peritonitis, acute pancreatitis, prior aminoglycoside
administration, and mechanical ventilation as independent
predisposing factors for infection.
ICU infections and multi-resistance are attributed to sev-
eral causes such as decreased host resistance, poor compli-
ance with hygiene regimes, inadequate disinfection or
sterilization of devices and equipment, prolonged use of
invasive devices and hospitalization, overcrowding and inef-
ficient isolation of infected patients, and inappropriate anti-
biotic use.1,4,6,7,10—12,21—23 A combination of effective
infection control measures is, thus, required.21
In our study, univariate analysis for risk factors for
mortality of patients with infection revealed a significant
association with age, APACHE II score on the day of SICU
admission, SOFA score on the day of infection diagnosis,
acute pancreatitis, superior mesentery artery infarction,
VAP, E. faecium infection, and mechanical ventilation prior
to infection. Furthermore, multivariate analysis identified
age, APACHE II score on admission, SOFA score on the day of
infection diagnosis, and VAP as independent risk factors for
mortality of patients with infection. Since VAP is the only
parameter potentially amenable to interventions among
these factors, our results highlight the significance of
implementation of effective VAP prevention measures in
ICUs.
The most effective antimicrobial agents for Gram-positive
organisms were linezolid, teicoplanin, and vancomycin. High
resistance of S. aureus and S. epidermidis to methicillin was
observed, whereas few isolates were resistant to vancomycin
and teicoplanin; in contrast, all isolates were susceptible to
linezolid. All isolates of enterococci were susceptible to
linezolid, while high resistance to all other antibiotics was
noted. High methicillin-resistant S. aureus (MRSA)1,3,7 and
vancomycin-resistant enterococci (VRE) or glycopeptide-
resistant enterococci (GRE)3,29 incidence along with resis-
tance of S. aureus to vancomycin29,30 have also been noted in
other studies. This high prevalence of GRE is an endemic
phenomenon in our unit that highlights the urgent need for
prompt implementation of rigorous and effective measures
for prevention, control, and treatment of GRE infections in
our patients, and of strategies to prevent and control the
selection and spread of these organisms. A combination of
several such measures has been implemented in our unit in
the last years. Even though detailed analysis of more recent
data has not been completed, our progress so far has been
good, and we believe that our results are encouraging.
Though considerable improvements have been made, we still
have a long way to go.Colistin was the only particularly effective antibiotic for
Gram-negative bacteria in our study. Although differences
regarding the antimicrobial resistance patterns of A. bau-
mannii, P. aeruginosa, and K. pneumoniae infections have
been identified, high resistance to most commonly used
antibiotics has been found in several studies.9,21,25,26 A sub-
stantial portion of these strains are susceptible only to
colistin. In our study, no strains resistant to colistin were
identified. In accordance with our results, resistance to
colistin appears to be rare.25,26 Moreover, the safety and
efficacy of colistin treatment in multi-resistant nonferment-
ing Gram-negative bacillus infections has been reported in
other studies.25,26 In an era of continuously increasing rates
of infections with multi-resistant pathogens, the develop-
ment of newer therapeutic alternatives to address the pro-
blem of such multi-drug resistance is, therefore, of the
utmost importance.
The high incidence of multi-resistant ICU infections sug-
gests thatmore effective strategies are needed to control the
selection and spread of resistant organisms.9,21 Organization
of infection prevention and control programs, pathogen and
antibiotic surveillance, and antibiotic use optimization are
crucial to reduce infection incidence, prevent multi-resis-
tance, reduce hospital costs, and improve patient prog-
nosis.9,12,21 Empiric treatment should be based on unit-
specific data.2,12,21 Since each hospital unit has a distinct
bacteriological profile and antibiotic resistance pattern,
knowledge of these differences is critical for planning effec-
tive therapy and reducing infection-related costs, morbidity,
and mortality.7,12,21
In conclusion, infections are a very important problem in
our SICU, associatedwith high incidence, complication rate,
mortality, and multi-drug resistance of the responsible
microorganisms. Eradication requires implementation of
rigorous infection control measures, prudent antibiotic
use, and effective antimicrobial therapy. Recognition of
clinical andmicrobiological characteristics of these patients
is essential for prevention and treatment of infections. In our
study, APACHE II score on admission, peritonitis, acute pan-
creatitis, previous aminoglycoside use, andmechanical ven-
tilation were identified as risk factors for infection
development, whereas age, APACHE II score on admission,
SOFA score at the onset of infection, andVAPwere associated
with mortality.
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